Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC® platform, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. GelrinC® may offer an alternative to traditional microfracture and complex cell-based therapies.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The product has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
The Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate the cartilage in a controlled process. The company emphasizes that no off-the-shelf treatment is currently available for the estimated 470,000 annual U.S. cases of cartilage knee repair.
For more information, visit the company's newsroom at https://ibn.fm/RGNT. A full corporate profile is available at https://ibn.fm/bpPp6.
